Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | CFD | P00746 | 7/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500386 | 0.82 | PARP1 (0.45) | PARP1RIPK1CFDMDM2 | |
| SCHEMBL6467428 | 0.79 | ITK (0.47) | ITKRIPK1IRAK4 | |
| SCHEMBL6506696 | 0.78 | ITK (0.56) | ITKIRAK4 | |
| SCHEMBL6500409 | 0.77 | ITK (0.55) | ITKIRAK4L3MBTL1 | |
| SCHEMBL6468684 | 0.77 | ITK (0.47) | ITKPARP1IRAK4L3MBTL1 | |
| SCHEMBL6506661 | 0.75 | ITK (0.48) | ITKPARP1RIPK1IRAK4L3MBTL1 | |
| SCHEMBL6506527 | 0.75 | SCN9A (0.46) | ITKIRAK4 | |
| SCHEMBL6497396 | 0.74 | SCN9A (0.43) | ITKPARP1IRAK4 | |
| SCHEMBL6497902 | 0.74 | SCN9A (0.43) | ITKPARP1IRAK4MDM2 | |
| SCHEMBL6506908 | 0.74 | ITK (0.42) | ITKPARP1IRAK4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ITK 4236/4885PARP1 1904/4885RIPK1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.